Migraine headache without aura has at least 5 attacks of any 2 symptoms of unilateral headache that is throbbing or pulsating in nature, moderate to severe in pain and activity aggravates pain. It is accompanied with either nausea and vomiting or photophobia &/or phonophobia. The symptoms last for 4-72 hours without signs of secondary headache.
Migraine headache with aura has at least 2 attacks with any of the fully reversible symptoms of flickering lights, spots or lines &/or vision loss, sensory symptoms
of pins & needles &/or numbness and dysphasic speech disturbance but without motor weakness. Accompanied by at least 2 of the following symptoms of homonymous visual symptoms &/or unilateral sensory symptoms or at least 1 aura symptoms develop gradually over ≥5 minutes &/or different aura symptoms that occur in succession over ≥5 minutes.
Calcitonin gene-related peptide (CGRP)-directed therapy with erenumab appears to effectively reduce the number of migraine days in patients with episodic migraine who have failed other preventive treatments due to lack of efficacy or low tolerability, according to the results of the phase IIIb LIBERTY trial.
New drug applications approved by US FDA as of 15 - 30 September 2018 which includes New Molecular Entities (NMEs) and new
biologics. It does not include Tentative Approvals. Supplemental approvals may
have occurred since the original approval date.
applications approved by US FDA as of 1 - 15 September 2018 which includes New Molecular Entities (NMEs) and new
biologics. It does not include Tentative Approvals. Supplemental approvals
may have occurred since the original approval date.
Individuals who have failed between two and four preventive therapies for episodic migraine may derive benefit from a once-a-month dose of erenumab, according to results of the phase IIIb LIBERTY* study.
Migraine may potentially increase the risks of myocardial infarction, ischaemic stroke, haemorrhagic stroke, venous thromboembolism, and atrial fibrillation or atrial flutter, according to a recent study. In addition, migraine may be a significant predictor for most cardiovascular diseases.
Fully monoclonal antibodies that target the calcitonin gene–related peptide (CGRP), particularly fremanezumab and erenumab, show potential in migraine prevention, significantly reducing the frequency of attacks in patients with chronic or episodic migraine, according to data from two phase III trials.
Osteopathic manipulative therapy (OMT) demonstrates therapeutic potential in patients with high-frequency migraine and comorbid mood disorders, with the improvements observed after four 45-minute OMT sessions, a study has shown.
A history of migraine headache is a predictor of increased risk of future cardiovascular (CV) events (cardiovascular death, nonfatal myocardial infarction, heart failure or stroke) on long-term follow-up among women being evaluated for ischaemic heart disease, according to a study. Moreover, this risk is mainly driven by a more than twofold rise in stroke risk.
Clinicians often face the dilemma of overinvestigating headaches caused by benign ailments and overlooking headaches that are manifestations of serious underlying conditions, despite advances in diagnostic techniques.
Use of standard-dose aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) appears to confer protection against the risk of endometrial cancer in overweight and obese women, according to a meta-analysis.
Less than 15 percent of Singaporean adolescents get the recommended 8–10 hours of sleep on a school night, reports a recent study, noting that such short sleep duration is linked to symptoms of depression, overweight or obesity, and poorer self-rated health.
Obstructive sleep apnoea may increase the risk of male-pattern baldness in men with a family history of hair loss, and this association appears to be mediated by low serum transferrin saturation levels related to hypoxia, a study suggests.